Skip to content

RedHill’s opaganib shows encouraging action against SARS-CoV-2 in preclinical

September 8, 2020

RedHill Biopharma (RDHL +12.0%) announces encouraging results from a preclinical study assessing protease inhibitor opaganib in an in vitromodel of human lung bronchial tissue. Opaganib completely inhibited SARS-CoV-2 replication.

Opaganib is currently being evaluated in a global Phase 2/3 trial and a U.S. Phase 2 study in severely ill COVID-19 patients with pneumonia.

Opaganib demonstrated the most potent activity compared to all compounds tested, including the positive control, Gilead Sciences’ (GILD -2.4%) remdesivir.

In addition to Opaganib, RedHill’s in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107.

A U.S. Phase 2/3 study with RHB-107 in an outpatient setting should launch later this year.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: